International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Pathophysiology of Stroke: A Molecular Mechanism Perspective

Avani N. Joshi[1], Kausar M. Sanghani[2], Akshita D. Moradiya[3], Mihir H. Bhatt[4], Sachin Bhatt[5]

[1,5]Assistant Professor, Department of Pharmacy, Gyanmanjari Pharmacy College
[2,3,4]Student, Bachelor of Pharmacy, Gyanmanjari Pharmacy College

Abstract
Stroke is a major cause of death and disability worldwide. The Resulting burden on the society continues to grow, with increase in the incidence of Stroke. Brain attack is a term introduced to describe the acute presentation of stroke, which emphasizes the need for urgent action to remedy the situation. While these observations underpinned key trials of thrombolysis, they also indicate that only patients who are likely to benefit should be exposed to its risks. This review explores the etiology and pathogenesis of ischemic stroke, and provides general information of model. This literature review examines the risk factors associated with ischemic stroke, changes in cell morphology and signaling in the brain after stroke. The Pathophysiology of cerebral ischemic injury is explained, and experimental animal models of global and focal ischemic stroke, and *in vitro* cellular stroke models, are described in details along with mechanism. This article is dedicated to acute ischemic strokes and its molecular mechanism. Classification systems for stroke a etiology are also discussed briefly, as well as current ischemic stroke therapies and new therapeutic strategies and clinical studies that focus on the potential of stroke recovery.

Keywords: Ischemic stroke, Hypertension, microglia cells, neutrophils, thrombosis, embolism

Introduction:

The second biggest cause of death worldwide is stroke and is the major cause of morbidity, particularly in the middle aged and elderly population. Stroke, according to the American Heart Association (AHA) definition, is a sudden loss of brain function due to disturbance in the cerebral blood supply with symptoms lasting at least 24 hours or leading to death [1]. Statins are having an ability to accommodate a new therapeutic goal for latitudinal neurological disorders. It is well observed that statins decrease levels of cholesterol and anticipate CHD. Furthermore, attestations proposed that in addition to antioxidant, anti-inflammatory and anti-platelet effects, statins have supplementary possessions like endothelial protection through action on the nitric oxide synthetase system [2].

Types of Strokes:

The five types of strokes are medical emergencies that stop or interrupt the flow of blood to the brain.
I) Ischemic Stroke (Oxygen deprivation stroke),
II) Hemorrhagic Stroke (Rupturing of Blood vessels),
III) Transient Ischemic Attack (Mini-Stroke),

IV) Brain Stem Stroke and
V) Cryptogenic Stroke (stroke of unknown cause) [3].

Risk factors:

In this era, there are so many challenging causes which are responsible for stroke and certain major issues related to our health and lifestyle. There are some basic warning signs for stroke:

1. Face drooping
2. Arm weakness
3. Speech difficulty.

In human stroke, cerebral vessel occlusion is seldom permanent, as most cases of human ischemic stroke have spontaneous or thrombolytic therapy-induced reperfusion [4,5]. Quality of life (QOL) is an important aspect of a complete outcome's evaluation, to document the effects of rehabilitation for persons with disabilities, including those with stroke [6]. The risk of ischemic stroke between patients with increased risk of vascular disease is reduced by treatment with statins [7].

Some of them are diabetes, high blood pressure, smoking, high cholesterol level which includes low density lipoprotein and high-density lipoprotein, lack of physical exercise, high consumption of alcohol and certain various factors [8].

Due to obesity also and eating junk food can sometimes be dangerous to the person as like we see in the case of stroke it is necessary to be healthy and fit [9]. Studies said that lipid is responsible for atherosclerotic stroke whereas arterial fibrillation is associated with cardio-embolic stroke [10].

The last decades have seen mixed evidence of BP management and apoplexy [11]. The connection of high BP and stroke risk is well included in large hygiene studies, and the BP lowering interest the apoplexy risk reduction is clearly confirmed by well-designed randomized controlled trials (RCTs)[12]. Since the occurrence and impermanence of apoplexy as well as major cardiovascular events increase with increasing BP levels beyond 115/75 mm Hg, among patients with acute apoplexy, BP is elevated in 70-75% of the patients. Mentioning high BP and physiological or pathological responses to acute apoplexy likely contribute to the increased BP [13]. However, the classic BP management during the acute stage still remains uncertain, particularly in patients with acute chlorosis stroke [14].

Pathophysiology:

The three main pathology of ischemic strokes are:

a) Thrombosis b) Embolism and c) Global ischemia (hypertensive) stroke

a) Thrombosis: Cerebral thrombosis refers to the formation of a blood clot inside an artery such as internal carotid artery, intracranial vertebral arteries and proximal artery which produce lacunas, small infarcts to typical places including basal ganglia, thalamus, internal capsule, pons and cerebellum [15] that develop at the clogged part of the vessel. Atherosclerosis is the reason for vascular obstruction resulting in thrombotic stroke [16]. Atherosclerotic plaques can undergo pathological changes such as blood clogging and blood clotting. Platelet adherence and obstruction to the vascular vessels follow, forming small nidi of platelets and fibrin [17,18]. When the mechanism of collateral circulation refuses, perfusion is compromised, leading to cell death [19].

b) Embolism: Cerebral embolism refers generally refers to a blood clot that develops in a different location in the circulatory system, typically the heart and major arteries of the upper neck and chest [20]. Embolic

stroke occurs when a clot breaks, loose and is carried by the blood stream and gets wedged in medium-sized branching arteries [21]. Embolism to the brain may be arterial or cardiac in region. Commonly recognized heart sources for embolism include atrial fibrillation, sinoatrial disorder, recent acute myocardial infarction (AMI), sub-acute bacterial endocarditis, cardiac tumors, and valvular disorders, both native and artificial [22]. In approximately one-third of ischemic stroke patients, embolism to the brain starts from the heart, especially in atrial fibrillation [23].

c) Global Ischemic or Hypotensive stroke: A third mechanism of ischemic stroke and clot is systemic hypoperfusion due to a generalized loss of arterial pressure [24]. Certain processes can lead to systemic hypoperfusion, the most majorly recognized and studied being cardiac arrest due to myocardial infarction and/or arrhythmia or severe hypotension (shock)[25]. Global ischemia is worse than hypoxia, hypoglycemia, and seizures because, in addition to cause energy loss, it results in accumulation of lactic acid and other toxic metabolites that are normally discarded by the circulationn [26].

Molecular Mechanism:

1. Resident microglia and blood-derived macrophages

Microglial cells, the resident macrophages of the brain, are activated hastily in response to intelligence damage [27]. Experimental statistics have proven that resident microglia are activated within minutes of ischemia onset and produce a plethora of proinflammatory mediators, which includes IL-1 and TNF, which exacerbate tissue injury [28] however might also additionally defend the brain towards ischemic and excitotoxic harm.

Post ischemic microglial multiplication crests at 48–72 h after central cerebral ischemia and may be final for a few weeks after beginning injury [29]. In differentiate to the fast inhabitant microglia response, blood-derived leukocytes are enrolled to the brain tissue, usually with a delay of hours to some days [30]. In any case, responsive microglia are morphologically and functionally comparative to blood-derived monocyte/macrophages [31]. To date, it has been troublesome to recognize these cells in the brain, as there's a need of separating cellular markers [32]. Blood-derived macrophages are able to procure a ramified morphology vague from inhabitant microglia, and receptive inhabitant microglia can create into a phagocytic phenotype vague from invading macro- phages. Luckily, the utilize of chimeric mice with the GFP bone marrow gives an effective apparatus to recognize their roles and commitments in ischemic brain damage [33]. Most current information has appeared that blood-derived macrophages are enlisted into the ischemic brain tissue, most abundantly at Days 3–7 after stroke (but not noteworthy earlier to 3 days after cerebral ischemia) [34]. It shows that inhabitant microglial enactment goes before and predominates over blood-derived macrophage invasion after transient MCAO in a chimeric mouse demonstrate [35]. These considers demonstrated that neutrophils are the primary blood-derived leukocytes seen at Day 1 within the harmed brain, though blood-derived macrophages (GFP-positive) were seldom watched at Day 2 but reached top numbers at Day 7 and diminished from there on [36]. In contrast, inhabitant microglial cells (GFP-negative) are already activated quickly at Day 1 after central cerebral ischemia. Intriguingly, indeed at Days 4 and 7, most macrophage-like cells remain GFP-negative, demonstrating that they are inhabitant microglia-derived; be that as it may, in mouse models of temporal MCAO and permanent MCAO, others illustrate that blood-derived macrophages (Iba1-positive) are invaded into the brain 24–48 h after central cerebral ischemia, but the number of the infiltrating macrophages remains much lower than activated resident microglia[37]. Together, most current information back the hypothesis that the endless lion's share of macrophage-like cells in the ischemic brain

speaks to enacted inhabitant microglia, especially amid the primary few days taking after cerebral I/R harm[38].

2. Neutrophils

Of the different sorts of leukocytes, neutrophils are among the first to invade ischemic brain (30 min to many hours of focal cerebral ischemia), top prior (Days 1–3), and after that disappear or diminish quickly with time [39]. Be that as it may, the infiltrating neutrophils may stay more than 3 days or longer in the ischemic brain after central cerebral I/R, but most likely, their presence is generally veiled after 3 days by large-scale accumulation of enacted microglia/macrophages within the inflammatory location [40]. Be that as it may, an curiously perception is that the penetration of other fiery cells, including macrophages, lymphocytes, and DCs, within the ischemic hemi- sphere goes before the neutrophilic deluge [41].

3. T lymphocytes

Prior considers recommend that lymphocyte enrollment into the brain is included within the afterward stages of ischemic brain injury [42]. In later years, increasing inquire about endeavors have been committed to the parts of specific T cell subtypes in ischemic stroke. There are many subtypes of lymphocytes, and a few subtypes of T cells have been ensnared within the pathogenesis of ischemic stroke [43]. In any case, the time course of the enrollment of different subtypes of T cells into the ischemic brain remains to a great extent undetermined.

4. Other inflammatory cells

In expansion to the over leukocytes, a few other sorts of inflammatory cells such as DCs and MCs have been implicated recently in ischemic brain damage. These incendiary cells are considered as early responders to act within the first-line defense in reaction to cerebral ischemia. In a mouse show of transient MCAO, it appears that DCs gathered in the ischemic half of the globe at 24 h after focal cerebral ischemia, particularly within the border region of the infarct where T cells accrued [44]. MCs within the brain are ordinarily found peri vascularly and contain strong, fast-acting vasoactive and proteolytic substances. In any case, there are vital limitations of these approaches. For stream cytometric investigation, there is a have to be confine cells from brain tissue utilizing enzymatic digestion ex vivo. The surface antigens for particular sorts of inflammatory cells may be balanced after the enzymatic digestion [45] In addition, immune-histochemistry and stream cytometry cannot examine energetic modification within the same creature as a result of a nonsurvivable strategy. So also, our current information about adhesive intuitive of incendiary cells with cerebral microcirculation after cerebral I/R is based on optical imaging technologies (particularly on intravital microscopy), which allow for perception and evaluation of cell grip to the walls of intaglio cerebral micro vessels[46].There are important limitations of these approaches, counting the ought to examine micro vessels on or close the brain surface, labeling the total leukocyte populace, and being incapable to survey early and late cement occasions within the same creature as a result of a nonsurvivable strategy. Of note, there are numerous inconsistencies in the literature approximately the time course of the recruitment of various inflammatory cells within the brain taking after central cerebral ischemia, indeed within the exceptionally same test creature models [47].

With changes in imaging innovation and labeling methods, such as positron emanation tomography/single photon emission tomography and utilitarian MRI, it has presently become possible to look at precisely fiery cell trafficking and the atomic movement (e.g., MPO and oxidative activity)

noninvasively in ischemic brain parenchyma in living animals [48]. Advanced imaging strategies and exploratory approaches will give the opportunity to imagine and evaluate more directly the energetic profiles of particular provocative cell trafficking, cement intelligent, and atomic action of these inflammatory cells with cerebral microcirculation and with each other within the brains of living creatures at early and late stages of cerebral I/R[49]. The application of such imaging technologies and approaches ought to offer assistance to address a few important unanswered questions around how these cells contribute to ischemic brain harm differentially and collaboratively [50].

Role of activated microglia macrophages in cerebral Ischemic damage

Inhabitant microglial cells are major incendiary cells in the brain that are among primary cells to reply to brain injury, and numerous lines of prove have appeared that actuated microglia play a double part in ischemic stroke. Microglia apply neurotoxic capacities through the generation of ROS via NADPH oxidase [51], cytokines (IL-1, IL-6, TNF) and MMP-9[52]. These occasions go before leukocyte infiltration into the brain and may play a pivotal part in interceding the initial increment in BBB porousness and the early infiltration of circulating leukocytes into the brain [53]. Microglia activation potentiates harm to BBB astuteness, while inhibition of microglial actuation may ensure the brain after ischemic stroke by progressing BBB practicality and astuteness in vivo and in vitro [54]. In differentiate, actuated microglia too show up to play a neuroprotective part after cerebral ischemia [55]. Generation of neurotoxic and neuroprotective components emphasizes the complex part of inhabitant microglia within the prepare of tissue damage, neuronal survival, and recovery within the reaction to cerebral ischemia. The defensive part of microglia is conceivably mediated by their capacity to dispense with abundance excitotoxins in the extracellular space, in portion through phagocytosis of infiltrating neutrophils [56]. Encourage, collecting prove indicates that microglia can create different neurotrophic variables such as neurotrophies and development components (fibroblast development factor, TGF-1), which are included in neuronal survival and brain tissue repair in cases of brain harm [57]. Intriguingly, recent work has distinguished a neuroprotective part for microglia derived TNF in cerebral ischemia through TNF-p55R in mice [58].

Tentatively, TNF has neuroprotective and neurotoxic effects. In spite of the fact that TNF can be delivered by microglia and infiltrating leukocytes within the brain, microglia and the neuroprotective impacts of TNF show up to be credited to microglia- but not leukocyte- derived TNF. These discoveries may have clinical pertinence and potential applications[59]. TNF is ensnared in ischemic stroke and injury in people, where comparative to the mouse[60], it is delivered by microglia and penetrating leukocytes[61].

In expansion, plenteous prove demonstrates a neuroprotective part of multiplying microglial cells in cerebral ischemia in vivo[62]. Particular removal of multiplying microglial cells worsens ischemic rain damage related with a decrease in insulin-like development factor-1 and an increment in cytokines (IL-1, IL-6, TNF-α) [63].

As examined over, actuated microglia is morphologically and practically undefined from blood-derived monocyte/macrophages within the brain. Hence, it has been troublesome to determine their particular commitment to the pathogenesis of ischemic stroke [64]. All things considered, the distinction of the time course of their enlistment within the brain suggests that they contribute to ischemic brain harm completely different time-dependent manners. Exploratory considers utilizing GFP bone marrow chimera mice show that blood-derived macrophage infiltration into the brain happens at

a afterward time after central cerebral I/R [65]. These considers have uncovered noteworthy differences in terms of the proportion and commitment of inhabitant microglia versus exogenous penetrating macrophages to early post- ischemic cerebral damage. Inhabitant microglia rules over blood-derived macrophages amid the primary 3–4 days of cerebral I/R [66]. Within the absence of blood-derived monocytes, brain microglia is able to distinguish into macrophages [67]. Notwithstanding of their beginning, enacted microglia/macrophages seem to be basic within the clearance of invading neutrophils after cerebral I/R. As discussed above, neutrophil infiltration occurs within the to begin with 3 days after cerebral I/R, and thereafter, macrophage-like cells replace them as the prevailing inflammatory cells within the ischemic location. The major pathway for clearance of penetrating neutrophils and their possibly cytotoxic substances from the fiery destinations is apoptosis taken after by engulfment by actuated microglia/macrophages [68]. Macrophages can resolve neutrophils and thus, decrease neuronal harm by activating neutrophil apoptosis, overwhelming them, and in this manner anticipating the discharge of cytotoxic substances into the encompassing tissue [69]. Acceptance of apoptosis and phagocytosis of apoptotic neutrophils by receptive microglia/ macrophages could be a basic step within the determination of the inflammatory reaction and in anticipating advance compounding of the ischemic harm [70]. In a rodent demonstrate of endothelin-1-induced cerebral ischemia, It demonstrate that large-scale resettlement of neutrophils into the ischemic region happens amid the primary day and crests at 3 days after cerebral ischemia [71]. Double immunostaining clearly appears that macrophages (recolored by ED-1) immerse neutrophils (recolored by anti-polymorphonuclear neutrophil sera) within the brain and that this engulfment of attacking neutrophils increments with time (50% of neutrophils within the brain are inundated at 3 days and 85% at 15 days) [72]. All things considered, it is hazy whether the “ED-1-stained cells” within the brain speak to actuated resident microglia or/and penetrating macrophages.

In any case of their beginning, actuated microglia/macrophages seem to be basic within the clearance of invading neutrophils after cerebral I/R. As discussed above, neutrophil infiltration occurs within the to begin with 3 days after cerebral I/R, and thereafter, macrophage-like cells replace them as the prevailing inflammatory cells within the ischemic location [73]. The major pathway for clearance of penetrating neutrophils and their possibly cytotoxic substances from the incendiary locales is apoptosis taken after by engulfment by actuated microglia/macrophages [74]. Macrophages can resolve neutrophils and so, decrease neuronal harm by activating neutrophil apoptosis, inundating them, and subsequently avoiding the discharge of cytotoxic substances into the encompassing tissue[75]. Acceptance of apoptosis and phagocytosis of apoptotic neutrophils by responsive microglia/ macrophages could be a basic step within the determination of the inflammatory reaction and in anticipating encourage worsening of the ischemic damage [76]. In a rodent demonstrate of endothelin-1-induced cerebral ischemia, demonstrate that large-scale displacement of neutrophils into the ischemic region happens amid the primary day and crests at 3 days after cerebral ischemia[77]. Double immunostaining clearly appears that macrophages (recolored by ED-1) inundate neutrophils (recolored by anti-polymorphonuclear neutrophil sera) within the brain and that this engulfment of attacking neutrophils increments with time (50% of neutrophils within the brain are immersed at 3 days and 85% at 15 days)[78]. All things considered, it is vague whether the “ED-1-stained cells” within the brain speak to actuated resident microglia or/and invading macrophages[79].

Prevention:

Primary prevention of ischemic stroke

The main ambition of acute and primary prevention is to decrease the risk of ischemic stroke (IS) in asymptomatic patients and elaborates on managing known risk factors such as arterial hypertension (AH), diabetes mellitus (DM) and lipid metabolism disorders [80]. Summarizing all strokes, approximately 70% are first-time events, thus primary-care physicians have a great opportunity to identify patients who may be benefitted from risk factor modification. In these settings, initiation of acute prevention strategies may have the highest impact on the disease and its biggest toll on the healthcare system [81].

Antihypertensive drugs: Increased systolic pressure, with or without an accompanying elevation in diastolic pressure, has been shown to increase stroke risk. BP decrease was associated with a 32% risk reduction in stroke problems [82].

Clinical Studies:

Multiple hygiene studies showed that high BP was associated with an increased risk of stroke impermanence. A large collaborative meta-analysis of individual participant data from 61 expected observational studies (958,074 individuals with 12.7 million person-years follow-up; 56,335 vascular deaths including 11,960 stroke deaths, 34,283 ischemic heart disease deaths, and 10,092 other vascular deaths) showed that, for BP≥115/75 mm Hg, the risk of stroke impermanence in all age groups significantly high with high BP levels, and the association of BP was greater with stroke impermanence than with ischemic heart disease mortality[83]. In individuals aged 40–69 years, every 20 mm Hg decrease in systolic BP (SBP) or 10 mm Hg decrease in diastolic BP (DBP) was associated with more than 2-fold decrease in the stroke impermanence [84].

High BP is associated with an increased risk of stroke incidence as well as stroke impermanence. The Asia Pacific Cohort Studies Collaboration study including 58 cohort studies (more than 3 million person-year follow-up and 5,178 stroke incidental cases) showed that the risk of stroke incidence high with high BP levels in a dose-dependent manner from the SBP level of 115 mm Hg[85]. For every 10 mm Hg reduced in SBP, the expected risk reduction of stroke incidence was 54% (95% confidence interval [CI] 53–56%), 36% (34–38%) and 25% (22– 28%) in individuals with age <60, 60–69, and ≥70 years, respectively. For both men and women and for both chlorosis and extravasate strokes, the risk increased with high BP levels[86].

For North American and European populations, an earlier meta-analysis already demonstrated the association of high BP and stroke incidence. Within the range of DBP 70–110 mm Hg, DBP reduction of 5 mm Hg, 7.5 mm Hg, and 10 mm Hg was associated with 34%, 46%, and 56% reduction of stroke risk[87].

In the updated INTERSTROKE phase 2 study with a large standardized case-control set of 26,919 individuals from 32 countries worldwide showing that 10 adjustable risk factors collectively accounted for about 90% of population-attributable risk for all stroke, high BP defined as self-reported hyper- tension or BP≥140/90 mm Hg had the largest population-attributable risk of 47.9% (99% CI 45.1–50.6). The population-attributable risk was 45.7% (42.4–49.0) for ischemic stroke and 56.4% (52.0–60.6) for intracerebral hemorrhage (ICH)[88]. The contribution of hypertension to regional stroke burden was greater in Asian region than in Europe, North America, and Australia[89].

Population-based studies observed in developed countries suggested that BP control contributes to the reduction of stroke incidence and mortality. In a Unite Kingdom study, between 1981 and 2004, first ever stroke fell by 29% (relative risk [RR] 0.71, 95% CI 0.61–0.83), ischemic stroke by 27% (0.73, 0.62– 0.86),

and primary ICH by 53% (0.47, 0.27–0.83), which was likely attributed to the improvement in risk factor control and antiplatelet use. Mean BP reduced from 156.3/88.0 mm Hg to 147.6/82.0 mm Hg, and the proportion of taking antihypertensive agents increased from 19.8% to 47.3%[90].

The Framingham Study of the United States (US) also showed that, over the periods of 1950–1977, 1978–1989, and 1990– 2004, the age-adjusted incidence of first-ever stroke fell by 25% (RR 0.75, 95% CI 0.59–0.95) in men and 24% (0.76, 0.61– 0.94) in women. During the study period, risk factor profiles except for diabetes significantly improved, which likely accounted for the decline in the stroke incidence. From 1950–1977 to 1990–2004, the proportion of individuals with BP>140/90 mm Hg reduced from 48% to 34% in men and from 56% to 30% in women, and the proportion of taking antihypertensive agents increased from 11% to 37% in men and from 19% to 27% in women[91]. In the US, stroke average has also declined since the early 20th century, resulting in repositioning stroke from the third to the fourth leading cause of death. The National Health and Nutrition Examination Survey data indicated a reduction of SBP in US population (mean SBP, 131 mm Hg in 1960–1962 and 122 mm Hg in 2001–2008), which might explain the de- cline in the stroke impermanence[92].

Among Asian studies, the Hisayama study in Japan showed a substantial decline in stroke incidence. The age-adjusted incidence for ischemic stroke significantly declined by 37% for men and by 32% for women from the first unit (enrolled in 1961) to the second unit (enrolled in 1974), and 29% for men and 14% for women from the second unit to the third unit (enrolled in 1988). The age-adjusted incidence of ICH also declined in men and women, particularly with a huge reduction of 61% from the first cohort to the second unit in men. During the period, the prevalence of severe high BP defined as BP≥160/100 mm Hg significantly decreased from 19.1% to 11.2% in men and from 17.9% to 12.0% in women along with increasing use of antihypertensive agents from 2.1% to 14.3% in men and 2.2% to 15.3% in women[93].

Discussion

Due to stroke, many people in the world are suffering. It leads to death of numerous people annually. There are basically two types of stroke: ischemic and Hemorrhagic.

Sudden numbness or weakness in the face, arm, or leg, mainly on one side of the body, sudden confusion, trouble spelling, or difficulty in understanding speech, sudden trouble seeing in one or both eyes are the symptoms of stroke. Actually what happens when you have stroke? When brain cells die, brain function is disturbed and lost. You may not be able to perform the things that are controlled by that part of the brain. For example, a stroke may affect your ability to move, speak, eat, think and remember, affect your bowel and bladder, control your emotions and control other necessary body functions.

A stroke, sometimes called a "brain attack," it happens when blood flow to an area in the brain is stopped. The brain cells, when decrease of the oxygen and glucose needed to survive, die. If not examined early, permanent brain damage and death can result. Stress results in the heart to work harder, increase blood pressure, and increase sugar and fat levels in the blood. These things, in turn, can highly increase the risk of clots formation and travelling to the heart or brain, causing a heart attack or stroke. A silent stroke means a stroke that doesn't cause any noticeable symptoms and nothing is felt. Most strokes are caused by a clot that blocks a blood vessel in the brain. The blockage affects blood and oxygen from reaching that area, causing nearby brain cells to die. Hemorrhagic stroke mainly requires surgery to relieve intracranial (within the skull) pressure caused due to bleeding. Surgical treatment for hemorrhagic stroke caused by an aneurysm or defective blood vessel cannot cause additional strokes. For instance or a time period, some

individuals may feel pain in their head due to a headache. Others may not feel any physical sensations but may disturbed to speak, which can lead to emotions of panic and confusion.

Ischemic stroke, the most usual type of stroke, is examined with the 'clot-busting' drug known as tPA. The drug must be administered to patients within three- to four-and-a-half hours after the onset of stroke symptoms, and preferably sooner.

REFERENCE

1. Kopyta I, Zimny N., Significant risk factors in the etiology of arterial ischemic stroke in children. CNS. 2015; (1):6-10.
2. Sree Lekshmi. R.S., P. Shanmugasundaram2*, Neuroprotective Properties of Statins. 2018; 11(8): 3581-3584.
3. Stoll G, Kleinschnitz C, Nieswndt B. Molecular Mechanisms of Thrombus Formation in Ischemic Stroke: Novel Insights and Targets for Treatment. Blood. 2008; 112(9):3555-3562.
4. Osama A K, Aziz A A, Saeed J, Fawzy M S., Thyroid Dysfunction in Acute Ischemic Stroke in Medical Intensive Care Unit in Zagazig University Hospitals. International Journal of Advanced Research. 2014; 2(7): 385-391.
5. Hinkle J L, Guanci M M. Acute Ischemic Stroke Review. Journal of Neuroscience Nursing.2007; 39(5):285-310.
6. Ali Deeaa K. Abd*, Quality of Life of Patients with Ischemic Stroke versus Hemorrhagic Stroke: Comparative Study. 2018, 11(11): 4911-4915
7. Lekshmi R. S. Sree1, Shanmugasundaram P.2*, Neuroprotective Properties of Statins. 2018, 11(8): 3581-3584
8. Olson, Marian B., et al. "Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBI-sponsored WISE study." Journal of the American College of Cardiology 36.5 (2000): 1565-1571.Aggarawal A, Aggarwal P, Khatak M, Khatak S., Cerebral Ischemic Stroke: Sequels Of Cascade. International Journal of Pharma and Bio Sciences, 2010; 1(3):1-24.
9. Mondol, Edward Probir. "the Role of Vr Games To Minimize the Obesity of Video Gamers." International Journal of Computations, Information and Manufacturing (IJCIM) 2.1 (2022).
10. Laloux, Patrice, Laurence Galanti, and Jacques Jamart. "Lipids in ischemic stroke subtypes." Acta neurologica belgica 104.1 (2004): 13-19.Lo E H, et al. Mechanism, Challenges and opportunities in stroke. Nature Reviews. Neuroscience. 2003; 4:399-414.
11. Zandieh A, et al. A simple risk score for early ischemic stroke mortality derived from National Institutes of Health Stroke Scale: A discriminant analysis. Clinical Neurology and Neurosurgery. 2013; 115:1036–1039
12. Moretz, Deanna. "Drug Class Update with New Drug Evaluation: Drugs for Endometriosis and Uterine Fibroids." (2021).
13. Rankin, John. "Cerebral vascular accidents in patients over the age of 60: II. Prognosis." Scottish medical journal 2.5 (1957): 200-215.
14. Chen, Li, et al. "Recent progress in targeted delivery vectors based on biomimetic nanoparticles." Signal transduction and targeted therapy 6.1 (2021): 225.
15. Aggarawal A, Aggarwal P, Khatak M, Khatak S., Cerebral Ischemic Stroke: Sequels Of Cascade. International Journal of Pharma and Bio Sciences, 2010; 1(3):1-24.

16. Shah S. Stroke Pathophysiology, Foundation for Education and Research in Neurological Emergencies (FERNE) 1-15.
17. Lakhan S E. et al. Inflammatory mechanism in ischemic stroke: Therapeutic approaches. Journal of Translational Medicine. 2009; 7:97-99.
18. Lo E H, et al. Mechanism, Challenges and opportunities in stroke. Nature Reviews. Neuroscience. 2003; 4:399-414.
19. Hinkle J L, Guanaco M. Acute Ischemic Stroke Review. Journal of Neuroscience Nursing. 2007; 39(5):285-310.
20. Tu, Jiyuan, et al. "The Human Cardiovascular System." Computational Hemodynamics–Theory, Modelling and Applications (2015): 21-42.
21. Caplan, Louis R., Roger P. Simon, and Sara Hassani. "Cerebrovascular disease—stroke." Neurobiology of Brain Disorders. Academic Press, 2023. 457-476.
22. Mohr J P, et al. Etiology of stroke. Stroke.1997; 28:1501-1506.
23. Shah S. Stroke Pathophysiology, Foundation for Education and Research in Neurological Emergencies (FERNE) 1-15.
24. Gasecki, Dariusz, et al. "Blood pressure in acute ischemic stroke: challenges in trial interpretation and clinical management: position of the ESH working group on hypertension and the brain." Journal of Hypertension 36.6 (2018): 1212-1221.
25. Mitchinson M J. The Hypotensive Stroke. Lancet. 1980; 1(8162):244-246.
26. Agamanolis D P. Cerebral Ischemia and Stroke. Neuropathology. 2013
27. Aloisi, F. (2001) Immune function of microglia. Glia 36, 165–179.
28. Banati, R. B., Gehrmann, J., Schubert, P., Kreutzberg, G. W. (1993) Cytotoxicity of microglia. Glia 7, 111–118.
29. Lalancette-He´bert, M., Gowing, G., Simard, A., Weng, Y. C., Kriz, J. (2007) Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27, 2596–2605.
30. Schilling, M., Besselmann, M., Leonhard, C., Mueller, M., Ringelstein, E. B., Kiefer, R. (2003) Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol. 183, 25–33.
31. Tanaka, R., Komine-Kobayashi, M., Mochizuki, H., Yamada, M., Furuya, T., Migita, M., Shimada, T., Mizuno, Y., Urabe, T. (2003) Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience 117, 531–539.
32. Schilling, M., Besselmann, M., Muller, M., Strecker, J. K., Ringelstein, E. B., Kiefer, R. (2005) Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol. 196, 290–297
33. Yilmaz, G., Arumugam, T. V., Stokes, K. Y., Granger, D. N. (2006) Role of T lymphocytes and interferon- in ischemic stroke. Circulation 113, 2105–2112.
34. Petry, K. G., Boiziau, C., Dousset, V., Brochet, B. (2007) Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 4, 434–442.

35. Schilling, M., Strecker, J. K., Scha¨bitz, W. R., Ringelstein, E. B., Kiefer, R. (2009) Effects of monocyte chemoattractant protein 1 on bloodborne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 161, 806–812.
36. Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Lysko, P. G., Feuerstein, G. Z. (1997) Tumor necrosis factor-: a mediator of focal ischemic brain injury. Stroke 28, 1233–1244.
37. Rothwell, N., Allan, S., Toulmond, S. (1997) The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J. Clin. Invest. 100, 2648–2652.
38. Denes, A., Vidyasagar, R., Feng, J., Narvainen, J., McColl, B. W., Kauppinen, R. A., Allan, S. M. (2007) Proliferating resident microglia after focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 27, 1941–1953.
39. Yilmaz, G., Granger, D. N. (2008) Cell adhesion molecules and ischemic stroke. Neurol. Res. 30, 783–793.
40. Weston, R. M., Jones, N. M., Jarrott, B., Callaway, J. K. (2007) Inflammatory cell infiltration after endothelin-1-induced cerebral ischemia: histochemical and myeloperoxidase correlation with temporal changes in brain injury. J. Cereb. Blood Flow Metab. 27, 100–114.
41. Gelderblom, M., Leypoldt, F., Steinbach, K., Behrens, D., Choe, C. U., Siler, D. A., Arumugam, T. V., Orthey, E., Gerloff, C., Tolosa, E., Magnus, T. (2009) Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40, 1849–1857.
42. Jander, S., Kraemer, M., Schroeter, M., Witte, O. W., Stoll, G. (1995) Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J. Cereb. Blood Flow Metab. 15, 42–51.
43. Kriz, J. (2006) Inflammation in ischemic brain injury: timing is important. Crit. Rev. Neurobiol. 18, 145–157. 24. Schilling, M., Besselmann, M., Leonh
44. Felger, J. C., Abe, T., Kaunzner, U. W., Gottfried-Balckmore, A., GalToth, J., McEwen, B. S., Iadecola, C., Bulloch, K. (2009) Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav. Immun., Epub ahead of print.
45. Annane D, Ouanes-Besbes L, de Backer D, DU B, Gordon AC, Hernández G, Olsen KM, Osborn TM, Peake S, Russell JA, Cavazzoni SZ. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018 Jun;44(6):833-846.
46. Raina S, Missiakas D, Georgopoulos C. The rpoE gene encoding the sigma E (sigma 24) heat-shock sigma factor of Escherichia coli. EMBO J. 1995;14:1043–1055.
47. Stevens, S. L., Bao, J., Hollis, J., Lessov, N. S., Clark, W. M., StenzelPoore, M. P. (2002) The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res. 932, 110–119.
48. Bazak, R.; Houri, M.; El Achy, S.; Hussein, W.; Refaat, T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol. Clin. Oncol. 2014, 2, 904–908.
49. Wang, Z.; Yang, H.; Wu, Z.; Wang, T.; Li, W.; Tang, Y.; Liu, G. In Silico Prediction of Blood–Brain Barrier Permeability of Compounds by Machine Learning and Resampling Methods. ChemMedChem 2018, 13, 2189–2201.
50. Mabrouk, O.S.; Falk, T.; Sherman, S.J.; Kennedy, R.T.; Polt, R. CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study. Neurosci. Lett. 2012, 531, 99–103
51. Pun, P. B., Lu, J., Moochhala, S. (2009) Involvement of ROS in BBB dysfunction. Free Radic. Res. 43, 348–364.

52. Del Zoppo, G. J., Milner, R., Mabuchi, T., Hung, S., Wang, X., Berg, G. I., Koziol, J. A. (2007) Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 38 (Suppl.), 646–651.
53. Yenari, M. A., Xu, L., Tang, X. N., Qiao, Y., Giffard, R. G. (2006) Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37, 1087–1093.
54. Kitamura Y., Takata K., Inden M., Tsuchiya D., Yanagisawa D., Nakata J., et al.. (2004). Intracerebroventricular injection of microglia protects against focal brain ischemia. J. Pharmacol. Sci. 94, 203–206. 10.1254/jphs.94.203
55. Streit, W. J. (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40, 133–139.
56. A.B. Knott, G. Perkins, R. Schwarzenbacher, E. Bossy-Wetzel Mitochondrial fragmentation in neurodegeneration Nat. Rev. Neurosci., 9 (2008), pp. 505-518
57. Kato, H., Tanaka, S., Oikawa, T., Koike, T., Takahashi, A., Itoyama, Y. (2000) Expression of microglial response factor-1 in microglia and macrophages following cerebral ischemia in the rat. Brain Res. 882, 206– 211.
58. Lambertsen, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C., Nielsen, H. H., Haugaard, L. S., Wirenfeldt, M., Nielsen, M., Dagnaes-Hansen, F., Bluethmann, H., Faergeman, N. J., Meldgaard, M., Deierborg, T., Finsen, B. (2009) Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J. Neurosci. 29, 1319–1330.
59. Zaremba, J., Losy, J. (2001) Early TNF- levels correlate with ischemic stroke severity. Acta Neurol. Scand. 104, 288–295.
60. Gregersen, R., Lambertsen, K., Finsen, B. (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. 20, 53–65.
61. Dziewulska, D., Mossakowski, M. J. (2003) Cellular expression of tumor necrosis factor and its receptors in human ischemic stroke. Clin. Neuropathol. 22, 35–40.
62. Lambertsen, K. L., Meldgaard, M., Ladeby, R., Finsen, B. (2005) A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 25, 119–135.
63. Thapa, Komal, et al. "Emerging Targets for Modulation of Immune Response and Inflammation in Stroke." *Neurochemical Research* (2023): 1-28.
64. Easton AS. Neutrophils and stroke—can neutrophils mitigate disease in the central nervous system? Int Immunopharmacol. 2013;17:1218–1225. doi: 10.1016/j.intimp.2013.06.015.
65. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325–329.
66. Inoue H, Kondo A, Togari A. Activation of the peripheral sympathetic nervous system increased the expression of cyclooxygenase-2 (COX-2) mRNA in mouse calvaria. Neuroscience letters. 2003;338:37–40.
67. Jin R, Zhu X, Liu L, Nanda A, Granger DN, Li G. Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice. Stroke. 2013;44:1135–1143.

68. Meszaros, A. J., Reichner, J. S., Albina, J. E. (1999) Macrophage phagocytosis of wound neutrophils. J. Leukoc. Biol. 65, 35–42.
69. Meszaros, A. J., Reichner, J. S., Albina, J. E. (2000) Macrophage-induced neutrophil apoptosis. J. Immunol. 165, 435–441.
70. Neumann, J., Sauerzweig, S., Ro¨nicke, R., Gunzer, F., Dinkel, K., Ullrich, O., Gunzer, M., Reymann, K. G. (2008) Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: a new mechanism of CNS immune privilege. J. Neurosci. 28, 5965–5975.
71. Savill, J. (1997) Apoptosis in resolution of inflammation. J. Leukoc. Biol. 61, 375–380.
72. Weston, R. M., Jarrott, B., Ishizuka, Y., Callaway, J. K. (2006) AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischemia. Br. J. Pharmacol. 149, 712–723.
73. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805.
74. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. Resident Vδ1+ γδ T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol. 2007;178:4466–4472.
75. Steinman R M, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419–426.
76. Niessner A, Sato K, Chaikof E L, Colmegna I, Goronzy J J, Weyand C M. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-α Circulation. 2006;114:2482–2489.
77. H. Morrison, D. McKee, and L. Ritter, "Systemic neutrophil activation in a mouse model of ischemic stroke and reperfusion," Biological Research for Nursing, vol. 13, no. 2, pp. 154–163, 2011
78. Brill A., Fuchs T. A., Savchenko A. S., Thomas G. M., Martinod K., De Meyer S. F., et al.. (2012). Neutrophil extracellular traps promote deep vein thrombosis in mice. J. Thromb. Haemost. 10, 136–144. 10.1111/j.1538-7836.2011.04544.x
79. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., et al.. (2011). Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89, 311–317. 10.1189/jlb.0310162
80. Kirshner H S, Biller J, Callahan A S. Long-Term Therapy to Prevent Stroke. Journal of American Board of Family Medicine.2005; 18(6)528-540.
81. Ford A L. Primary Prevention Of Ischemic Stroke. European Neurological Review.2007; 1:24-28.
82. Goldstein L B, et al. Primary Prevention of Ischemic Stroke. Circulation. 2001; 103:163-182.
83. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40:795–796.]
84. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H, Valsartan in Elderly Isolated Systolic Hypertension Study G Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196–202.
85. Sabayan B, van Vliet P, de Ruijter W, Gussekloo J, de Craen AJ, Westendorp RG. High blood pressure, physical and cognitive function, and risk of stroke in the oldest old: the Leiden 85-plus study. Stroke 2013; 44:15–20.
86. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21:707-716.

87. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
88. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–775.
89. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21:707–716
90. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxford shire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363:1925-1933.
91. Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 2006; 296:2939-2946.
92. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/ American Stroke Association. Stroke 2014; 45:315-353.
93. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34:2349-2354.